Martina Korfei

TL;DR: Severe ER stress response in the AECIIs of patients with sporadic IPF may underlie the apoptosis of this cell type and development of fibrosis in this disease.

TL;DR: It is demonstrated that lung epithelial cells exhibit increased P16 and P21 expression as well as senescence-associated β-galactosidase activity in experimental and human lung fibrosis tissue and primary cells and that senolytic drugs may be a viable therapeutic option for IPF.

TL;DR: Novel drugs acting on highly activated fibroblasts such as pirfenidone, an anti-fibrotic drug authorised for IPF in the European Union, or BIBF 1120, a novel triple-kinase inhibitor currently under clinical investigation, seem to attenuate the progression of IPF.

TL;DR: Aberrant overexpression of HDACs in basal cells of IPF lungs may contribute to the bronchiolisation process in this disease and pan-HDAC inhibition by LBH589 may present a novel therapeutic option for patients with IPF.

TL;DR: It is shown that the majority of children with opsoclonus‐myOClonus syndrome have autoantibodies binding to the surface of isolated rat cerebellar granular neurons, and it is hypothesize that opsoconerous syndrome may be the result of an autoimmune process against a neuronal surface protein.